



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

CT

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/510,560	02/22/2000	Kenneth Iain Cumming	00.1090.US	3011
7590	06/14/2006		EXAMINER	
SYNNESTVEDT & LECHNER LLP ATTN: PATRICK J. KELLY, ESQ. SUITE 2600 ARAMARK TOWER 1101 MARKET STREET PHILADELPHIA, PA 19107-2950			LUNDGREN, JEFFREY S	
			ART UNIT	PAPER NUMBER
			1639	
			DATE MAILED: 06/14/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/510,560	CUMMING ET AL.
	Examiner	Art Unit
	Jeff Lundgren	1639

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 22 May 2006.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 96 and 97 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 96 and 97 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>see office action</u> .	6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

Reassignment of Application

Please note that this application has been reassigned to Examiner Jeffrey Lundgren. In order to expedite accurate processing of the application papers, all future correspondence with the Office should reflect this change.

Withdrawal of Allowable Subject Matter – Finality Maintained

The allowability of claims 96 and 97 are withdrawn, and the finality of the Office Action is maintained. Applicants have filed an information disclosure statement citing a document that necessitated the new grounds of rejection, however, Applicants did not provide a statement as required by 37 C.F.R. § 1.97(e). Accordingly, the finality of the Office Action is maintained.

An action on the merits is provided below explaining why the claims stand rejected over the art.

Status of the Claims

Claims 96 and 97 are pending in the captioned application, and are the subject of examination.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on November 10, 2005, has been considered by the Examiner. The submission is in compliance with the provisions of 37 CFR § 1.97. Enclosed with this Office Action is a return-copy of the Form PTO-1449 with the Examiner's initials and signature indicating those references that have been considered.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 96 and 97 are rejected under 35 U.S.C. 102(b) as being anticipated by Bachynsky *et al.*, Irish Patent No. (11) 63119, published on March 22, 1995.

Claim 96 is directed to a process for preparing a solid composition capable of forming a solid oral dosage form, wherein the composition comprises a blend of a hydrophilic drug or macromolecular drug, a second component and an optionally another constituent, wherein the blend and each component is a solid at room temperature.

Bachynsky teaches a process for providing a blend of a macromolecular drug (*i.e.*, ceftriaxon) and a salt of a medium chain fatty acid having a carbon chain length of from 6 to 20 carbon atoms (*i.e.*, sodium caprylate), with optional constituents Laureth-12 and Witepsol™ H15 (pages 14 and 15). The blend, as well as each of the drug, medium chain fatty acid salt, and the other constituents, each are solids at room temperature. The blend is capable of forming an oral dosage form, and the sodium caprylate would serve as an enhancer.

Claim 97 is directed to the ratio of the drug to enhancer in the range of 1:100,000 to 10:1.

The ratio of the drug to enhancer taught by Bachynsky is 0.3:1 to 1.5:1 (see table, page 14, lines 15-19).

Accordingly, claims 96 and 97 are anticipated by Bachynsky.

Conclusions

No claim is allowable.

Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p) on November 10, 2005, prompted the new grounds of rejection presented in this Office action. Accordingly, **THIS ACTION IS MAINTAINED AS FINAL**. See MPEP § 609.04(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

If Applicants should amend the claims, a complete and responsive reply will clearly identify where support can be found in the disclosure for each amendment. Applicants should point to the page and line numbers of the application corresponding to each amendment, and provide any statements that might help to identify support for the claimed invention (e.g., if the amendment is not supported *in ipsis verbis*, clarification on the record may be helpful). Should Applicants present new claims, Applicants should clearly identify where support can be found in the disclosure.


Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeff Lundgren whose telephone number is 571-272-5541. The Examiner can normally be reached from 7:00 AM to 5:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Peter Paras, can be reached on 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JSL

**PETER PARAS, JR.
PRIMARY EXAMINER**


SPE 1639